When response to endocrine environment was related to clinical characteristics, we found that those tumours which upregulated SRC-1 in the presence of oestrogen were all HER2-positive tumours and conversely those that could downregulate SRC-1 in response to tamoxifen were HER2 negative. Here, ERBB2 is linked to neoplasm.